IsoRay is the exclusive manufacturer of Cesium-131 and the GliaSite Radiation Therapy System. IsoRay's evolving product line is advancing brachytherapy treatments throughout the body giving new hope to physicians and patients. Cesium-131 allows for the precise treatment of many different cancers because of its unrivaled blend of high energy and its 9.7 day half-life (its unequaled speed in giving off therapeutic radiation). The GliaSite balloon catheter brings targeted dose to the local area needing radiation while limiting damage to healthy brain cells.
In addition to its CMS codes, Cesium-131 and GliaSite utilizing liquid I-125 are FDA-cleared and have CE marks for international sales. Cesium-131 is currently sold in seed form for the treatment of brain cancer, prostate cancer (http://www.isoray.com/prostate_cancer_treatment.asp), lung cancer, ocular melanoma cancer (http://www.isoray.com/ocular_cancer_treatment.asp), colorectal cancer, gynecologic cancer (http://www.isoray.com/gyn_cancer_treatment.asp), head and neck cancer (http://www.isoray.com/) and other cancers throughout the body. The treatment can be deployed using several delivery methods including single seed applicators, implantable strands and seed sutured mesh, and several new implantable devices.
IsoRay, Inc., through its subsidiary, IsoRay Medical, Inc. is the sole producer of Cesium-131 brachytherapy seeds, which are expanding brachytherapy options throughout the body. Learn more about this innovative Richland, Washington company and explore the many benefits and uses of Cesium-131 by visiting www.isoray.com. Join us on Facebook/Isoray (http://www.facebook.com/#/IsoRay). Follow us on Twitter @Isoray (https://twitter.com/#!/Isoray).
Safe Harbor Statement
Statements in this news release about IsoRay's future expectations, including: the advantages of our Cesium-131 seed, the advantages of the GliaSite Radiation Therapy System, whether adoption of Cesium-131 will continue to increase, whether IsoRay will be able to continue to expand its base beyond prostate cancer, whether revenue and other financial metrics will improve in future periods, whether Cesium-131 will become a standard of care for any cancer treatment, and all other statements in this release, other than historical facts, are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 ("PSLRA"). This statement is included for the express purpose of availing IsoRay, Inc. of the protections of the safe harbor provisions of the PSLRA. It is important to note that actual results and ultimate corporate actions could differ materially from those in such forward-looking statements based on such factors as physician acceptance, training and use of our products, our ability to successfully manufacture, market and sell our products, our ability to manufacture our products in sufficient quantities to meet demand within required delivery time periods while meeting our quality control standards, our ability to enforce our intellectual property rights, whether ongoing patient results with our products are favorable and in line with the conclusions of clinical studies and initial patient results, patient results achieved when Cesium-131 is used for the treatment of cancers and malignant diseases beyond prostate, whether we, our distributors and our customers will successfully obtain and maintain all required regulatory approvals and licenses to market, sell and use our products, successful completion of future research and development activities, and other risks detailed from time to time in IsoRay's reports filed with the SEC.
Most Popular Stories
- 5 Potential Snags to the Bipartisan Budget Deal
- Adam Levine Wins Big as 'The Voice' Crowns Champ
- Archer Daniels Midland Moving HQ to Chicago
- From Fiscal Cliff to Female Head of GM: 2013 in Review
- Budget Deal on Brink of Passing in Senate
- U.S. Home Construction Hammers Out 5-Year High
- Broadband Policies Could Mean 11,000 Jobs
- Senate Sends Bipartisan Budget Plan to President
- William Morris Endeavor Eats up IMG
- Wine Collector Convicted of Making Fake Vintages